Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel

Company Expects Growing Biosimilar Product Portfolio, Commercialized in Israel and the MENA Region, to Generate Approximately $10 Million in Annual Revenue in 2028 and Approximately $20 Million-$25 Million in Annual Revenue by 2030REHOVOT, Israel and HOBOKEN, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE…